Category Archives: Ventricular Remodeling

As Biotechnology companies, Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) and BioLineRx Ltd. (NASDAQ:BLRX) are our subject to contrast Continue reading →

This is a contrast between BioLineRx Ltd. (NASDAQ:BLRX) and Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) based on their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation. Continue reading →

The stock of Biolinerx LTD. American Depositary Shares (NASDAQ:BLRX) registered an increase of 13.43% in short interest Continue reading →

Both BioLineRx Ltd. (NASDAQ:BLRX) and Soligenix Inc. (NASDAQ:SNGX) compete on a level playing field in the Biotechnology industry Continue reading →

The inhibition of SGLT-2 was not associated with an improvement in left ventricular (LV) reverse remodeling in patients with type 2 diabetes mellitus (T2DM), new study results suggest. There is no known association between diastolic function parameters as determined by transthoracic echocardiography (TTE) and SGLT-2 inhibitor therapy, the paper authors, publishing in meeting supplement of the Journal of Cardiac Failure and presenting at the Heart Failure Society of American Scientific Meeting in Philadelphia. We hypothesized that in patients with T2DM the use of SGLT-2 inhibitors might improve TTE diastolic function parameters including LV mass and LV mass index Continue reading →

KIRKLAND, Wash Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the publication of the REDUCE FMR clinical study of its Carillon Mitral Contour System. Continue reading →

The 2019 Heart Failure Society of America Scientific Meeting (HFSA 2019) in Philadelphia has wrapped up. DocWire News was there, and reports here on some interesting research from the meeting Continue reading →

As per a report published by National Heart, Lung, and Blood Institute (NHLBI), heart failure incidences continue to rise in the United States with approximately 825,000 new cases diagnosed in 2013. As per NHLBI, 5.1 million Americans over the age of 20 have heart failures and this number is projected to increase by 46% to reach 8 million by 2030. Cardiac restoration systems are usually used after a coronary artery bypass grafting and may precede or be followed by mitral valve repair or other procedures such as endocardectomy and cryoablation. Continue reading →

PHILADELPHIA, PAPatients who have heart failure with reduced ejection fraction (HFrEF) achieve the most benefit in terms of survival and avoiding hospitalization when N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels are lowered quickly with sacubitril/valsartan, new data from the PROVE-HF trial show. The findings extend to patients with new-onset HF, and also suggest that even a suboptimal dose of the angiotensin receptor-neprilysin inhibitor (ARNI) gets the job done Continue reading →

Cardiac Dimensions today touted a clinical study of its Carillon mitral contour system in treating the primary cause of functional mitral regurgitation (FRM) in patients with heart failure. Carillon is a right heart transcatheter mitral valve repair (TMVR) device designed to treat FRM in patients with mitral regurgitation grades of 2+, 3+ and 4+ in heart failure. Continue reading →